Long-term asciminib treatment for people with chronic myeloid leukemia
Tests asciminib long term in people with chronic myeloid leukemia who finished an earlier study.
Plain-language title generated from the registry record
Registry title: Asciminib Roll-over Study
Key facts
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, and Wuerzburg, GermanySee the 22 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 7 and 100 years old?
- What type of cancer has the patient been diagnosed with?
- Is the patient pregnant or breastfeeding?
Source: NCT04877522, who can take part
Where in Germany
- Universitaetsklinikum Aachen AöRAachen, GermanyTaking people
- Universitaetsklinikum AugsburgAugsburg, GermanyTaking people
- HELIOS Klinikum Bad Saarow GmbHBad Saarow, GermanyTaking people
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
- Klinikum Chemnitz gGmbHChemnitz, GermanyTaking people
- Gemeinschaftspraxis Haematologie OnkologieDresden, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
- Martin-Luther-Universitaet Halle-WittenbergHalle (Saale), GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Universitaetsklinikum Jena KöRJena, GermanyTaking people
- Staedtisches Krankenhaus Kiel GmbHKiel, GermanyTaking people
- Universitaet LeipzigLeipzig, GermanyTaking people
- Heidelberg UniversityMannheim, GermanyTaking people
- Philipps-Universitaet MarburgMarburg, GermanyTaking people
- Haemato-Überoertliche Gemeinschaftspraxis Pasing und Fuerstenfeldbruck GbRMuenchen, GermanyTaking people
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
- Barmherzige Brueder gemeinnuetzige Krankenhaus GmbHRegensburg, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT04877522EU 2023-507557-16-00
- Record updated
- 9 November 2026
- Original description
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatmentRead full original descriptionShow less
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Inclusion: Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment; Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures.
Exclusion: Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information; Applicable for participants on bosutinib treatment at the end of the CABL001A2301 and on other TKIs for CABL001A2202 study that switch to asciminib treatment:; Asymptomatic (grade 2) pancreatitis if not resolved within 28 days; QTcF>480msec or inability to determine QTc interval; any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment; Other protocol-defined Inclusion/Exclusion criteria may apply; Participant has been discontinued from parent study treatment; Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study; Participant's ongoing treatment is currently approved and reimbursed at country level; Pregnant or nursing (lactating) women; Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment.